Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bishop

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologySobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Critical Care Medicine|June 4, 2024
Epinephrine Dosing Intervals Are Associated With Pediatric In-Hospital Cardiac Arrest Outcomes: A Multicenter StudyMartha F Kienzle, Ryan W Morgan, Ron W Reeder, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Trials|April 5, 2018
Improving outcomes after pediatric cardiac arrest - the ICU-Resuscitation Project: study protocol for a randomized controlled trialRon W Reeder, Alan Girling, Heather Wolfe, et al.
Cancer Discovery|April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsErick J Morris, Sharda Jha, Clifford R Restaino, et al.
Resuscitation|February 24, 2020
Variability in chest compression rate calculations during pediatric cardiopulmonary resuscitationWilliam P Landis, Ryan W Morgan, Ron W Reeder, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndromeLeslie B Gordon, Monica E Kleinman, David T Miller, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologySobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Critical Care Medicine|June 4, 2024
Epinephrine Dosing Intervals Are Associated With Pediatric In-Hospital Cardiac Arrest Outcomes: A Multicenter StudyMartha F Kienzle, Ryan W Morgan, Ron W Reeder, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Trials|April 5, 2018
Improving outcomes after pediatric cardiac arrest - the ICU-Resuscitation Project: study protocol for a randomized controlled trialRon W Reeder, Alan Girling, Heather Wolfe, et al.
Cancer Discovery|April 26, 2013
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsErick J Morris, Sharda Jha, Clifford R Restaino, et al.
Resuscitation|February 24, 2020
Variability in chest compression rate calculations during pediatric cardiopulmonary resuscitationWilliam P Landis, Ryan W Morgan, Ron W Reeder, et al.
Pageof 6